Our newest preprint is now online! We lift up the hood on TET2 mutant clonal hematopoiesis and show that oxidative metabolism is a critical feature of TET2 deficient HSPC - with compensatory redox control as a potential vulnerability.
https://t.co/t8wdEmvSrp
Happy to see our study finally published in @BCD_AACR! 🎉 Thanks again to the lead authors @mp_hartmann, Maximilian Schönung and all collaborators who helped to put together the bits and pieces of this exciting story! 🙏👏
Dr. Ross Levine (@rosslevinemd), Senior Vice President of Translational Research at MSK, has been named MSK's new Chief Scientific Officer (CSO).
Dr. Levine will be responsible for setting and leading strategy for basic and translational research, including programs, centers, and technology cores.
Congratulations, Dr. Levine!
https://t.co/0WFajs5Nsg
How it started (undergrad who thinks grant writing is fun🤓) vs how it’s going (A PAPER IN BLOOD🩸!) excited to share the FULL ATF6 story with the world! Thank you to my amazing co-authors and mentor @TheElfLab for helping my six year long dream come true! https://t.co/hArUnguTo9
I am deeply honored and immensly grateful to the scientific community at ISEH for receiving this award! And a big shoutout and thank you to all the brilliant and hard-working former and current members of my lab who made the progress possible that led to this award! 😊 🙏
Unsolicited advice to new PIs and my opinion only not fact:
As a new Assistant Professor, you have a 1-1.5 year window where you can get an R01 without a corresponding author paper IF you have a high impact 1st author paper from your postdoc.
After that, it seems no amount of data in your R01 application matters anymore. The study section is looking for a peer reviewed publication. The important thing here is that it does not need to be high impact. They are looking for execution. Can you deliver the final product?
“I don’t have time. Is there an alternative?” Put paper on preprint server and get it sent out at a respectable journal and note that in your R01 application. The study section may let this slide.
Again, my OPINION based on my own experience. Good luck to all new PIs I know it’s a tough time.
Delighted to see our CLN1 & CLN2 Enteric Nervous System gene therapy paper published in @ScienceTM today! Big team effort with many great colleagues @HeuckerothLab@WashUMedPeds & directly inspired by Batten families @BDSRA@NIH_NINDS@noahs_hope1 https://t.co/yTQSRXGY66
Excited to share our latest work published today in @SciImmunology and featured on the cover! This study demonstrates that thrombospondin-1 (Thbs1) is a driver of hematopoietic aging and that targeting Thbs1 suppresses inflammaging and restores systemic and HSC healthspan.